OGN earnings analysis
What we found in OGN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Organon reported declining financial performance for Q1 2026, with revenue of $1.460 billion and diluted EPS of $0.71, both missing analyst expectations. Notably, segments saw declines in Women’s Health and Established Brands, though some growth was recorded in Biosimilars. The ongoing merger with Sun Pharma complicates forward guidance as management shifts focus.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Missed Expectations
- Actual revenue of $1.460 billion fell short of the estimated $1.484 billion.
- EPS Missed Consensus
- Diluted EPS came in at $0.71, below the anticipated $0.84, reflecting a miss of 15.5%.
- Notable Segment Performance
- Revenue in Women's Health declined 19%, particularly impacted by Nexplanon sales dropping from $248 million to $201 million.
- Positive Cash Flow Generation
- Net cash provided by operating activities was $225 million for Q1 2026, up from $75 million in Q1 2025.
- Cash Reserves Increase
- Cash and cash equivalents rose to $1.12 billion as of March 31, 2026.
- Restructuring Cost Reduction
- Restructuring costs decreased significantly to $31 million from $86 million year-over-year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Pending Merger Risk
- The merger with Sun Pharma may not close as expected due to various regulatory and approval conditions.
- Material Weakness in Controls
- Continuing material weaknesses in internal control over financial reporting could impact reliability in financial disclosures.
- Sales Decline Across Key Products
- Nexplanon and other key products have seen significant declines in demand, signaling potential long-term challenges.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.71
- Segment
- Women's Health: $360 million, General Medicines: $1.100 billion
What they said about what is next.
No forward guidance provided due to ongoing merger with Sun Pharma.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OGN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever